Merck & Co., Inc. Proceeds from Sale of Intangible Assets
Merck & Co., Inc. (MRK) reported Proceeds from Sale of Intangible Assets of $132.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-08-07
- Merck & Co., Inc. proceeds from sale of intangible assets for the quarter ending 2026-06-30 was $132.00M, a 32.00% increase year-over-year.
- Merck & Co., Inc. proceeds from sale of intangible assets for the quarter ending 2026-03-31 was $132.00M, a 38.95% increase year-over-year.
- Merck & Co., Inc. proceeds from sale of intangible assets for the quarter ending 2025-12-31 was $27.00M, a 80.00% increase year-over-year.
- Merck & Co., Inc. proceeds from sale of intangible assets for the quarter ending 2025-09-30 was $11.00M, a 26.67% decline year-over-year.
- Merck & Co., Inc. proceeds from sale of intangible assets for fiscal 2025 was $138.00M, a 30.19% increase from fiscal 2024.
- Merck & Co., Inc. proceeds from sale of intangible assets for fiscal 2024 was $106.00M, a 10.17% decline from fiscal 2023.
- Merck & Co., Inc. proceeds from sale of intangible assets for fiscal 2023 was $118.00M, a 28.48% decline from fiscal 2022.
- Merck & Co., Inc. proceeds from sale of intangible assets for fiscal 2022 was $165.00M, a 24.31% decline from fiscal 2021.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 9 month as first filed | Proceeds from Sale of Intangible Assets 12 month | Proceeds from Sale of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $132.00M 10-Q · filed 2026-08-07 | $264.00M derived: sum of 2 quarters · filed 2026-08-07 | $291.00M derived: sum of 3 quarters · filed 2026-08-07 | $302.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $132.00M 10-Q · filed 2026-05-04 | $159.00M derived: sum of 2 quarters · filed 2026-05-04 | $170.00M derived: sum of 3 quarters · filed 2026-05-04 | $270.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $38.00M derived: sum of 2 quarters · filed 2026-02-24 | $138.00M derived: sum of 3 quarters · filed 2026-08-07 | $138.00M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $111.00M derived: sum of 2 quarters · filed 2026-08-07 | $111.00M 10-Q · filed 2025-11-05 | $221.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $100.00M 10-Q · filed 2026-08-07 | $100.00M 10-Q · filed 2025-08-05 | $210.00M derived: sum of 3 quarters · filed 2026-08-07 | $225.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $95.00M 10-Q · filed 2026-05-04 | $110.00M derived: sum of 2 quarters · filed 2026-05-04 | $125.00M derived: sum of 3 quarters · filed 2026-05-04 | $140.00M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $30.00M derived: sum of 2 quarters · filed 2026-02-24 | $45.00M derived: sum of 3 quarters · filed 2026-02-24 | $106.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $30.00M derived: sum of 2 quarters · filed 2025-11-05 | $91.00M 10-Q · filed 2025-11-05 | $91.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $76.00M 10-Q · filed 2025-08-05 | $76.00M derived: sum of 3 quarters · filed 2026-02-24 | $140.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $61.00M 10-Q · filed 2025-05-02 | $61.00M derived: sum of 2 quarters · filed 2026-02-24 | $125.00M derived: sum of 3 quarters · filed 2026-02-24 | $128.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $64.00M derived: sum of 2 quarters · filed 2026-02-24 | $67.00M derived: sum of 3 quarters · filed 2026-02-24 | $118.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $64.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $67.00M derived: sum of 2 quarters · filed 2024-11-06 | $118.00M 10-Q · filed 2024-11-06 | $127.00M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $54.00M 10-Q · filed 2024-08-05 | $63.00M derived: sum of 3 quarters · filed 2025-02-25 | $73.00M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-03-31 | $51.00M 10-Q · filed 2024-05-03 | $60.00M derived: sum of 2 quarters · filed 2025-02-25 | $70.00M derived: sum of 3 quarters · filed 2025-02-25 | $102.00M derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $19.00M derived: sum of 2 quarters · filed 2025-02-25 | $51.00M derived: sum of 3 quarters · filed 2025-02-25 | $165.00M 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $42.00M derived: sum of 2 quarters · filed 2023-11-03 | $156.00M 10-Q · filed 2023-11-03 | $183.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $146.00M 10-Q · filed 2023-08-07 | $173.00M derived: sum of 3 quarters · filed 2024-02-26 | $308.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $114.00M 10-Q · filed 2023-05-05 | $141.00M derived: sum of 2 quarters · filed 2024-02-26 | $276.00M derived: sum of 3 quarters · filed 2024-02-26 | $276.00M derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $162.00M derived: sum of 2 quarters · filed 2024-02-26 | $162.00M derived: sum of 3 quarters · filed 2024-02-26 | $218.00M 10-K · filed 2024-02-26 | $185.00M 10-K · filed 2022-02-25 | |
| 2021-09-30 | $135.00M 10-Q · filed 2021-11-05 | $135.00M derived: sum of 2 quarters · filed 2022-08-05 | $191.00M 10-Q · filed 2022-11-03 | $185.00M 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $56.00M 10-Q · filed 2022-08-05 | ||||
| 2021-03-31 | $56.00M 10-Q · filed 2022-05-05 | |||||
| 2020-12-31 | $54.00M 10-K · filed 2023-02-24 | |||||
| 2020-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $85.00M 10-Q · filed 2020-08-05 | ||||
| 2020-03-31 | $75.00M 10-Q · filed 2020-05-06 | |||||
| 2019-12-31 | $80.00M 10-K · filed 2020-02-26 | |||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $15.00M 10-Q · filed 2020-08-05 | $29.00M derived: sum of 3 quarters · filed 2020-08-05 | $39.00M derived: sum of 4 quarters · filed 2020-08-05 | ||
| 2019-03-31 | $15.00M 10-Q · filed 2020-05-06 | $29.00M derived: sum of 2 quarters · filed 2020-05-06 | $39.00M derived: sum of 3 quarters · filed 2020-05-06 | $89.00M derived: sum of 4 quarters · filed 2020-05-06 | ||
| 2018-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $24.00M derived: sum of 2 quarters · filed 2020-02-26 | $74.00M derived: sum of 3 quarters · filed 2020-02-26 | $95.00M 10-K · filed 2020-02-26 | ||
| 2018-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $60.00M derived: sum of 2 quarters · filed 2018-11-06 | $81.00M 10-Q · filed 2018-11-06 | $106.00M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $71.00M 10-Q · filed 2018-08-07 | $96.00M derived: sum of 3 quarters · filed 2020-02-26 | $106.00M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-03-31 | $21.00M 10-Q · filed 2018-05-08 | $46.00M derived: sum of 2 quarters · filed 2020-02-26 | $56.00M derived: sum of 3 quarters · filed 2020-02-26 | $56.00M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $35.00M derived: sum of 2 quarters · filed 2020-02-26 | $35.00M derived: sum of 3 quarters · filed 2020-02-26 | $85.00M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $10.00M derived: sum of 2 quarters · filed 2018-11-06 | $60.00M 10-Q · filed 2018-11-06 | $155.00M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $50.00M 10-Q · filed 2018-08-07 | $145.00M derived: sum of 3 quarters · filed 2019-02-27 | $145.00M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | $50.00M 10-Q · filed 2018-05-08 | $145.00M derived: sum of 2 quarters · filed 2019-02-27 | $145.00M derived: sum of 3 quarters · filed 2019-02-27 | $145.00M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $95.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $95.00M derived: sum of 2 quarters · filed 2019-02-27 | $95.00M derived: sum of 3 quarters · filed 2019-02-27 | $170.00M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $75.00M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $75.00M 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | $75.00M 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | $232.00M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |